Mesenchymal stem/stromal cell therapy for inflammatory bowel disease

Dave, Maneesh; Jaiswal, Palashkumar; Cominelli, Fabio

doi:10.1097/mog.0000000000000327

Cited by 29 publications

(21 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colitis, an inflammation of the colon, was treated with using intraperitoneal injection 10 5 -10 6 human ADSCs or murine ADSCs in a study[ 56 , 57 ]. This study was associated with reduced weight loss, improved survival and improved clinical in ADSC groups[ 57 ].…”

Section: Colitis Diseasementioning

confidence: 99%

Adipose-derived stromal cell in regenerative medicine: A review

Qomi

Sheykhhasan

2017

WJSC

View full text Add to dashboard Cite

The application of appropriate cell origin for utilizing in regenerative medicine is the major issue. Various kinds of stem cells have been used for the tissue engineering and regenerative medicine. Such as, several stromal cells have been employed as treat option for regenerative medicine. For example, human bone marrow-derived stromal cells and adipose-derived stromal cells (ADSCs) are used in cell-based therapy. Data relating to the stem cell therapy and processes associated with ADSC has developed remarkably in the past 10 years. As medical options, both the stromal vascular and ADSC suggests good opportunity as marvelous cell-based therapeutics. The some biological features are the main factors that impact the regenerative activity of ADSCs, including the modulation of the cellular immune system properties and secretion of bioactive proteins such as cytokines, chemokines and growth factors, as well as their intrinsic anti-ulcer and anti-inflammatory potential. A variety of diseases have been treated by ADSCs, and it is not surprising that there has been great interest in the possibility that ADSCs might be used as therapeutic strategy to improve a wider range of diseases. This is especially important when it is remembered that routine therapeutic methods are not completely effective in treat of diseases. Here, it was discuss about applications of ADSC to colitis, liver failure, diabetes mellitus, multiple sclerosis, orthopaedic disorders, hair loss, fertility problems, and salivary gland damage.

show abstract

Section: Colitis Diseasementioning

confidence: 99%

Adipose-derived stromal cell in regenerative medicine: A review

Qomi

Sheykhhasan

2017

WJSC

View full text Add to dashboard Cite

show abstract

“…Due to the intrinsic regenerative potential and immunomodulatory abilities, the stem cells (SCs) therapy has opened up a breakthrough approach to cure autoimmune disease. Meta-analyses of studies on SCs therapy indicated a certain potential to treat liver cirrhosis [3][4][5], chronic liver disease [6], inflammatory bowel disease [7] and ischemic heart disease [8]. SCs therapy also showed a potential effect to halt or abolish the autoimmune destruction of β cells and to generate functional β cells which could achieve optimized glycemic control in T1DM [9][10][11][12][13].…”

mentioning

confidence: 99%

Efficacy and safety of stem cells transplantation in patients with type 1 diabetes mellitus—a systematic review and meta-analysis

Zheng

Yao

et al. 2020

Endocr J

View full text Add to dashboard Cite

Stem cells (SCs) therapy is a new promising therapeutic modality for type 1 diabetes (T1DM). We performed a systematic review and meta-analysis to evaluate the efficacy and safety of stem cells transplantation (SCT) in patients with T1DM. We searched five literature databases (MEDLINE, EMBASE, Web of Science, WanFang and CENTRAL) up to 31 October 2019. 29 studies (487 patients with T1DM) were included in our meta-analysis. There was no substantial publication bias. Meta-analysis showed the SCT had significant effect to decrease HbA1c (SMD, 1.40; 95% CI, 0.93 to 1.86; p < 0.00001; I 2 = 89%) and to improve C-peptide levels (SMD,-0.62; 95% CI,-1.22 to-0.02; p = 0.04; I 2 = 92%) at 1 year follow-up. Subgroup analyses showed the heterogeneity level of the results was high. Significant improvement of metabolic outcomes was observed in the subgroups of mesenchymal stem cells (MSCs) combined with hematopoietic stem cells (HSCs) and HSCs. The older age showed significant association with the efficacy in HSCs subgroup. The higher GADA positive rate before treatment also significantly associated with the decrease of daily insulin requirement. The transient insulin independence rate at last follow-up was 9.6 per 100 person-years (95% CI: 5.8-13.5%). The mean length of insulin independence was 15.6 months (95% CI: 12.3-18.9). The mortality of SCT was 3.4% (95% CI: 2.1-5.5%). Therefore, SCT is an efficacious and safe method for treating patients with T1DM especially in the subgroups of MSCs + HSCs and HSCs. Well designed, double blind and randomized controlled trails with large sample size and long-term follow-up are needed for further evaluation.

show abstract

“…Recently, limitations of MSCs have been reported. For example, therapeutic effects were not long term and were affected by inflammatory condition [ 59 , 60 ]. Thus, the results of ongoing clinical studies will be expected to provide further insights.…”

Section: Resultsmentioning

confidence: 99%

Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases

et al. 2017

View full text Add to dashboard Cite

Mesenchymal stem cell (MSC) therapies have been used in clinical trials in various fields. These cells are easily expanded, show low immunogenicity, can be acquired from medical waste, and have multiple functions, suggesting their potential applications in a variety of diseases, including liver disease and inflammatory bowel disease. MSCs help prepare the microenvironment, in response to inflammatory cytokines, by producing immunoregulatory factors that modulate the progression of inflammation by affecting dendritic cells, B cells, T cells, and macrophages. MSCs also produce a large amount of cytokines, chemokines, and growth factors, including exosomes that stimulate angiogenesis, prevent apoptosis, block oxidation reactions, promote remodeling of the extracellular matrix, and induce differentiation of tissue stem cells. According to ClinicalTrials.gov, more than 680 clinical trials using MSCs are registered for cell therapy of many fields including liver diseases (more than 40 trials) and inflammatory bowel diseases (more than 20 trials). In this report, we introduce background and clinical studies of MSCs in liver disease and inflammatory bowel diseases.

show abstract

Mesenchymal stem/stromal cell therapy for inflammatory bowel disease

Cited by 29 publications

References 46 publications

Adipose-derived stromal cell in regenerative medicine: A review

Adipose-derived stromal cell in regenerative medicine: A review

Efficacy and safety of stem cells transplantation in patients with type 1 diabetes mellitus—a systematic review and meta-analysis

Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases

Contact Info

Product

Resources

About